全文获取类型
收费全文 | 86774篇 |
免费 | 5971篇 |
国内免费 | 1689篇 |
专业分类
耳鼻咽喉 | 277篇 |
儿科学 | 1659篇 |
妇产科学 | 974篇 |
基础医学 | 8396篇 |
口腔科学 | 1040篇 |
临床医学 | 10194篇 |
内科学 | 15369篇 |
皮肤病学 | 400篇 |
神经病学 | 4861篇 |
特种医学 | 2476篇 |
外国民族医学 | 2篇 |
外科学 | 6554篇 |
综合类 | 12101篇 |
现状与发展 | 6篇 |
一般理论 | 1篇 |
预防医学 | 12584篇 |
眼科学 | 657篇 |
药学 | 9494篇 |
68篇 | |
中国医学 | 4867篇 |
肿瘤学 | 2454篇 |
出版年
2024年 | 145篇 |
2023年 | 1189篇 |
2022年 | 1873篇 |
2021年 | 3362篇 |
2020年 | 3340篇 |
2019年 | 2512篇 |
2018年 | 2433篇 |
2017年 | 2616篇 |
2016年 | 2803篇 |
2015年 | 2891篇 |
2014年 | 6144篇 |
2013年 | 6407篇 |
2012年 | 5534篇 |
2011年 | 5989篇 |
2010年 | 4646篇 |
2009年 | 4442篇 |
2008年 | 4303篇 |
2007年 | 3981篇 |
2006年 | 3624篇 |
2005年 | 3028篇 |
2004年 | 2548篇 |
2003年 | 2294篇 |
2002年 | 1877篇 |
2001年 | 1674篇 |
2000年 | 1437篇 |
1999年 | 1175篇 |
1998年 | 990篇 |
1997年 | 985篇 |
1996年 | 846篇 |
1995年 | 817篇 |
1994年 | 722篇 |
1993年 | 669篇 |
1992年 | 578篇 |
1991年 | 517篇 |
1990年 | 521篇 |
1989年 | 443篇 |
1988年 | 470篇 |
1987年 | 436篇 |
1986年 | 390篇 |
1985年 | 494篇 |
1984年 | 466篇 |
1983年 | 302篇 |
1982年 | 380篇 |
1981年 | 322篇 |
1980年 | 325篇 |
1979年 | 224篇 |
1978年 | 211篇 |
1977年 | 185篇 |
1976年 | 173篇 |
1973年 | 147篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
61.
Walid K. Abu Saleh Phillip Mason Odeaa Al Jabbari Hany Samir Brian A. Bruckner 《Texas Heart Institute journal / from the Texas Heart Institute of St. Luke's Episcopal Hospital, Texas Children's Hospital》2015,42(6):569-571
The Impella 5.0, a percutaneously inserted left ventricular assist device, has been used to support patients who have severe heart failure or who are undergoing high-risk percutaneous coronary intervention. We report our surgical placement of the Impella 5.0, through a graft sewn to the aorta, to unload the left ventricle of a 59-year-old man who was undergoing venoarterial extracorporeal membrane oxygenation for postcardiotomy shock. The patient underwent successful placement of a long-term left ventricular assist device before his discharge from the hospital. The versatility of the Impella 5.0 is exemplified in this patient who was successfully bridged to long-term support. 相似文献
62.
目的观察并比较枸橼酸咖啡因及氨茶碱对早产儿不同时相血糖的影响程度。方法选择新生儿监护室诊断为原发性呼吸暂停的出生胎龄<34周的早产儿172例,采用随机数字表法分为咖啡因组与氨茶碱组各86例。比较两组早产儿用药前及用药后15、30min、1、1.5、2、4、6、12、12.5、24.5、36.5和48h血糖的变化。结果两组早产儿用药后除6、12和48h血糖值比较差异均无统计学意义(均P>0.05),其他用药后时相比较差异均有统计学意义(均P<0.05)。咖啡因组早产儿用药后30min血糖值上升,至1h达峰值,后逐渐回落;用药后30min、1、1.5、2及24.5h血糖值与用药前比较差异均有统计学意义(均P<0.05)。氨茶碱组早产儿用药后血糖值上升,30min达峰值,后逐渐回落;用药后15、30min、1、1.5、2、4、6、12.5、24.5、36.5h血糖值与用药前比较差异均有统计学意义(均P<0.05)。结论枸橼酸咖啡因可引起早产儿血糖升高,但升高幅度较氨茶碱小、持续时间也较短。 相似文献
63.
Implications for Practice
Breast cancer is far more curable than in the past but requires multimodality treatment. Great care must be taken to use the least leukemogenic treatment programs that do not sacrifice efficacy. Elimination of radiation and anthracycline/alkylating agent regimens will be helpful where possible, particularly in younger patients and possibly those with homologous repair deficiency (HRD). Use of colony-stimulating factors should be limited to those who truly require them for safe chemotherapy administration. Further study of a possible leukemogenic association with HRD and the various forms of colony-stimulating factors is badly needed.64.
65.
目的:分析鼻塞式同步间歇正压通气(NIPPV)联合布地奈德雾化治疗ARDS(新生儿急性呼吸窘迫综合征)疾病的临床应用效果。方法:纳入病例是2017年5月—2019年11月收治的104例ARDS新生儿,随机平均分为两组。参照组52例采纳CPAP(持续气道正压通气通气)治疗,实验组52例采纳NIPPV+布地奈德雾化治疗,对比两组呼吸机通气时间、用氧时间、住院时间、血气指标以及并发症发生情况。结果:实验组呼吸机通气时间、用氧时间、住院时间均明显短于参照组,差异有统计学意义P<0.05;实验组治疗3 d后PaCO2明显低于参照组,实验组治疗3 d后PH以及PaO2明显高于参照组,差异有统计学意义P<0.05;实验组并发症发生率(3.85%,2/52)明显低于参照组(21.15%,11/52),差异有统计学意义P<0.05。结论:NIPPV+布地奈德雾化可有效缩短ARDS患者机械通气时间,改善血气指标,降低并发症发生率,值得借鉴。 相似文献
66.
目的:探讨玉液汤对2型糖尿病肥胖患者肠道菌群及脂质代谢影响。方法:选取2017年2月至2019年2月广州市中医医院收治的2型糖尿病肥胖患者106例作为研究对象,按照就诊顺序分为对照组和观察组,每组53例。2组均给予基础治疗+药物治疗,观察组再加用玉液汤治疗。观察2组治疗前、完成治疗后肠道菌群、脂质代谢、中医症状积分、血糖相关指标、体质量、腰围、体质量指数(BMI)变化并比较。结果:2组治疗前各指标比较差异无统计学意义(P>0.05),完成治疗后观察组患者的中医症状积分、FINS、HOMA-IR、HbAlc、BMI、腰围、体质量、TC、TG、LDL-C、肠杆菌、酵母菌、肠球菌、畏寒肢冷、腰膝酸软、脘腹2组患者治疗后HDL-C、双岐杆菌、乳杆菌、拟杆菌均较治疗后明显上升,且观察组高于对照组(P<0.05)。结论:玉液汤能改善2型糖尿病肥胖患者脂质代谢和临床症状,降低血糖,能调节肠道菌群紊乱,从而提高疗效。 相似文献
67.
68.
《Transfusion and apheresis science》2020,59(4):102855
The activation of the innate and adaptive immune systems by SARS-CoV-2 causes the release of several inflammatory cytokines, including IL-6. The inflammatory hypercytokinemia causes immunopathological changes in the lungs including vascular leakage, and alveolar edema. As a result of these changes in the lungs, hypoxia and acute respiratory distress syndrome occur in patients with COVID-19. Even though there are clinical trials on the development of therapeutics and vaccines, there are currently no licensed vaccines or therapeutics for COVID-19. Pharmacological approaches have shown poor results in sepsis-like syndromes caused by the hypercytokinemia. Suppressing the cytokine storm is an important way to prevent the organ damage in patients with COVID-19. Extracorporeal blood purification could be proposed as an adjunctive therapy for sepsis, aiming to control the associated dysregulation of the immune system, which is known to protect organ functions. Several extracorporeal blood purification therapies are now available, and most of them target endotoxins and/or the cytokines and aim improving the immune response. For this purpose, plasmapheresis and immunoadsorption may be an important adjunctive treatment option to manage the complications caused by cytokine storm in critically ill patients with COVID-19. 相似文献
69.
经典名方泽泻汤的HPLC指纹图谱及多指标含量测定研究 总被引:2,自引:0,他引:2
目的建立经典名方泽泻汤的HPLC指纹图谱,结合化学模式识别技术对其进行分析,并测定泽泻汤中3种成分23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的含量,为泽泻汤质量控制提供科学依据。方法采用Waters WAT054275C18色谱柱(250 mm×4.6 mm,5μm),以乙腈-水为流动相进行梯度洗脱,建立15批泽泻汤的HPLC指纹图谱,并采用"中药色谱指纹图谱相似度评价系统"、SPSS22.0及SIMCA14.1软件对15批泽泻汤的HPLC指纹图谱进行相似度评价及聚类分析(CA)、偏最小二乘判别分析(PLS-DA)等化学模式识别。同时测定23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的含量。结果建立了15批泽泻汤的HPLC指纹图谱,相似度均0.94,标定了18个共有峰,指认出3个色谱峰,分别为11号峰白术内酯Ⅲ、15号峰23-乙酰泽泻醇C、16号峰23-乙酰泽泻醇B,CA和PLS-DA将15批泽泻汤样品分为2类,同时15批泽泻汤中23-乙酰泽泻醇B、23-乙酰泽泻醇C和白术内酯Ⅲ的质量分数分别为0.321~0.569、0.075~0.139、0.106~0.142 mg/g。结论 HPLC指纹图谱结合多成分同时测定的方法,快速、简便、重复性好,为泽泻汤及其制剂的质量评价提供参考。 相似文献
70.
《Revista espa?ola de anestesiología y reanimación》2022,69(9):517-525
Background and objectivesThe ideal timing of tranexamic acid administration in total knee arthroplasty with tourniquet remains unclear. Our primary objective was to prove if administering it before surgical incision, instead of before releasing the tourniquet, reduces postoperative bleeding. A second objective was to determine whether a second dose reduces post-operative bleeding.Material and methodsA prospective, double-blind clinical trial was performed on 212 patients scheduled for total knee arthroplasty. They were randomised into 4 groups. Tranexamic acid was administered before the surgical incision in “pre-induction groups” (1 and 2), and just before the tourniquet release in “pre-release groups” (3 and 4). Groups 2 and 4 received a second dose 3 hours post-surgery. Main outcome was postoperative bleeding (visible blood loss and calculated total bleeding). Secondary outcomes were haemoglobin variations, complications and transfusion rate.ResultsThe mean calculated total bleeding was 1563 ml (95%CI: 1445 to 1681) in preinduction groups versus 1576 ml (95%CI: 1439 to 1713) in pre-release groups (P = .9); 1579 ml (95%CI: 1452 to 1706) in single-dose groups versus 1559 ml (95%CI: 1431 to 1686) in double-dose groups (P = .82). One patient was transfused. The mean haemoglobin at discharge was 10.4 g/dl (95%CI: 10.2 to 10.7) in singledose groups versus 10.8 (95%CI: 10.6 to 11.1) in double-dose groups (P = .06).ConclusionsThere were no differences in bleeding or transfusion regarding the time of tranexamic acid administration. The second dose had not impact on outcomes.Trial registration: EudraCT 2016-000071-24. 相似文献